Sitagliptin accepted as monotherapy in Scotland
By Tom Moberly, 20 July 2010
Sitagliptin has been accepted for restricted use as monotherapy for type-2 diabetes in the NHS in Scotland.
Thee Scottish Medicines Consortium (SMC) has accepted the treatment for patients with type-2 diabetes for whom both metformin and sulphonylureas are inappropriate.
The SMC said that research had shown sitagliptin worked as well as metformin in patients who had received no previous treatment for diabetes.
But, it added, no data are available to compare the effectiveness of sitaglipin with other medicines taken as monotherapy.
Further Reading
- Related Drug Categories
- Insulins
- Related MIMS Tables
- Finger Prickers and Compatible Lancets
- Insulin Preparations
- Blood Glucose Testing Strips and Meters
- Related MIMS Guidelines and Summaries
- Liraglutide for the Treatment of Type 2 Diabetes Mellitus
- Current Medical Standards of Fitness to Drive
- Management of Type 2 Diabetes
Additional Information
Latest jobs Jobs web feed
- Full time GP partner - Isle of Man Laxey and Village Walk Health Centres Competitive, Isle of Man
- Salaried GP Dr K.T. Tattum FRCGP Competitive, Stockton Brook, Stoke-on-Trent, Staffordshire
- General Practitioner x 2 for MOD, RAF Leuchars, Fife MMP Competitive hourly rates offered, East Coast of Scotland
- General Practitioner for Gamecock Barracks, Nuneaton MMP Competitive hourly rates, West Midlands
- GP for MOD, RAF Waddington, Lincs MMP Competitive hourly rates offered, Lincoln
- Locum GP for central east London Surgey HealthCare&Locum Recruitment Ltd Negotiable, Central london
Most read
- NHS reforms: Interactive Health Bill timeline
- Exclusive: 'Stop the mudslinging on pensions' says BMA chairman
- Royal colleges step up Health Bill opposition
- Male GPs more likely to experience burnout than female colleagues
- GPC warns of 'target culture' as GP commissioning framework revealed
- Vaccinate teenagers against meningitis, say DH advisers
Most commented
MIMS Drug Search
Possible searches include drugs (by brand, generic ingredient or drug class), diseases and more.
